Creative Biolabs integrates diverse ligand repertoires with flexible selection formats. We offer biomarker exploration, functional screening, and interaction-focused validation to ensure relevant outputs for target nomination.
Explore Discovery & Validation Workflows
Creative Biolabs integrates Phage Display Applications with tailored target discovery and validation strategies to support the transition from broad biological questions to more defined, research-ready target hypotheses. Our service covers biomarker-oriented exploration, functional target screening, and interaction-focused validation, with workflows adapted to purified proteins, domains, peptides, target-expressing cells, and other research materials. By aligning screening strategy with target format, biological context, and downstream study goals, we help improve the relevance of selection outputs for subsequent target evaluation.
Many early discovery programs lose momentum when screening design, target presentation, and validation planning are not considered together. Phage display helps address this issue by combining diverse ligand repertoires with flexible selection formats, allowing investigators to enrich binders under conditions that better match the intended research setting. With appropriate counter-selection, sequence analysis, and staged validation, this approach can generate data that support target nomination, candidate ranking, and follow-up study design.
We support early-stage target discovery and validation projects across oncology, immunology, infectious disease, neuroscience, metabolic research, and cell signaling. Depending on the study objective, we can help identify disease-associated biomarkers, prioritize functionally relevant targets, define binding preferences, compare target states, and generate validated hit sets for downstream mechanistic research. For projects with an existing candidate target, we can also design validation-oriented studies focused on selectivity, context relevance, and downstream experimental usability.
This service is particularly useful when a project requires more than a standard screening workflow and instead calls for a target discovery strategy matched to a specific biological question. Creative Biolabs can support studies such as the following:
Identification of candidate targets or target-associated molecular features that distinguish disease and control systems.
Comparison of multiple target hypotheses to support prioritization for further experimental investment.
Studies involving membrane-associated or context-dependent targets where native presentation may influence discovery outcomes.
Projects with preliminary leads that require stronger evidence for ranking, refinement, or downstream assay support.
Programs that need to connect target discovery with functional screening or interaction-focused follow-up rather than stopping at initial enrichment.
Research efforts that require a practical route from uncertain biological observations to a more focused list of target candidates.
For many researchers, the main question at this stage is whether the service fits the current phase of the project. If your study falls into one or more of these scenarios, a tailored phage display workflow may provide a useful route to target-focused insight.
Target discovery projects require more than access to high-diversity libraries. They require a platform that can connect screening design, target presentation, hit interpretation, and validation depth to a defined scientific objective. Creative Biolabs brings these elements together in a practical research workflow designed to improve the value of discovery-stage data.
We tailor screening strategies to purified proteins, membrane-associated targets, cell-surface molecules, and comparative systems aligned with the research objective.
Our validation design helps determine whether a candidate target is reproducibly enriched, distinguishable, and suitable for further target ranking and selection.
Creative Biolabs supports target discovery across biomarker research, functional screening, and interaction analysis for deeper follow-up work.
We organize outputs into ranked hits, comparative interpretations, and validation-focused findings to support triage and planning.
If your project involves a difficult target, an uncertain biological context, or limited starting information, share your goal with us for a tailored screening recommendation.
To support different discovery objectives, Creative Biolabs offers three closely related services that can be performed as a standalone project or incorporated into a broader target discovery and validation program. These services can also be combined in sequence.
This service supports the identification of disease-associated or condition-associated molecular signatures using phage display-based selection strategies. It is suitable for studies aimed at discovering distinguishing binders, characterizing differential recognition patterns, or generating research probes for biomarker-oriented investigation. Projects may involve purified molecules, cell populations, tissue-derived materials, or comparative screening formats designed to enrich context-selective candidates.
This route is intended for studies in which target relevance is linked to biological function rather than binding alone. Screening designs can be adapted to pathway-related questions, target modulation hypotheses, competitive or differential binding settings, and target classes in which functional context is important for meaningful hit selection. This is particularly useful for researchers seeking discovery outputs that are more informative for target prioritization.
This service supports target validation through interaction-focused evidence. It can be used to define binding regions, identify partner preferences, explore interaction motifs, or clarify whether a candidate target participates in a biologically relevant recognition network. For projects that require stronger support after initial discovery, interaction mapping can provide an additional layer of evidence before downstream experimental investment.
Target discovery and validation projects often require different screening environments depending on target accessibility, biological complexity, and the level of validation needed. To support these different research settings, Creative Biolabs offers multiple phage display platforms that can be selected according to target format, sample type, and downstream study goals. These platform options allow researchers to move from controlled in vitro screening to more biologically relevant validation settings as the project develops.
This platform is well suited to projects built around purified proteins, domains, peptides, recombinant ectodomains, enzymes, and other defined target materials. It provides a controlled setting for target-focused enrichment, comparative binding analysis, and early specificity assessment when the target is structurally accessible and experimentally well defined. For target discovery studies that begin with a known molecule or a focused target hypothesis, this is often a practical starting point.
This platform is particularly useful when native conformation, membrane localization, or cell-surface accessibility may affect discovery outcomes. By using target-expressing cells or relevant control cells, cell-based phage display can support the discovery of binders under conditions that better reflect the native biological context. It is often a suitable option for membrane proteins, cell-surface receptors, and projects in which context-dependent recognition is an important part of target evaluation.
For studies that require a more physiologically relevant setting than standard in vitro screening, this platform can provide additional support for target discovery and validation. Ex vivo phage display is useful when researchers need to assess candidate interactions in more complex biological materials, including tissue-related or clinically relevant research samples. This can be valuable for refining target relevance and supporting validation in settings that preserve more of the original biological background.
This platform can be incorporated when a project requires higher-level validation in animal models. In vivo phage display is particularly useful for evaluating target accessibility, tissue-associated binding patterns, and biological relevance under more complex physiological conditions. Within target discovery and validation programs, it is typically considered an advanced option for studies that need additional in vivo support beyond in vitro or ex vivo screening.
In practice, these platforms can be used independently or in combination, depending on the stage and objective of the project. A study may begin with a defined in vitro protein-based screening strategy, move into cell-based selection for context-relevant assessment, and later incorporate ex vivo or in vivo validation to strengthen biological relevance and downstream decision-making.
Review target hypothesis, biological context, materials, and validation depth required.
Select appropriate library and design biopanning strategy (targets, controls, selection pressure).
Perform screening workflow to iteratively recover enriched binders.
Identify enriched sequences, recurrent motifs, and prioritize hits.
Advance selected candidates to rebinding, context confirmation, and final reporting.
Well-defined project inputs improve discovery efficiency and help us align the screening strategy with the scientific objective. Even when the available information is limited, a clear description of the biological question can help us design a more informative study.
Target class or working hypothesis.
Purified proteins, peptides, cells, lysates, or related controls.
Preferred screening context, including protein-based or cell-based selection.
Biomarker exploration, functional target prioritization, or interaction validation.
A description of how the study design was matched to your target format and biological system.
A ranked candidate list or grouped hit set to support identification of sequences for follow-up.
Comparative enrichment and validation data to support target triage, beyond uninterpreted raw outputs.
A research-use-oriented conclusion with practical recommendations for downstream validation or next-stage design.
Target discovery projects often begin with incomplete information. You may have a candidate pathway but no confirmed target, or several possible directions. Send us your target type, sample format, and research goal for a tailored screening recommendation, even if your project is still at the hypothesis or comparison stage.
Start with What You Already KnowThe following studies illustrate how phage display can be applied from selective enrichment through target-focused confirmation, context-specific screening, and downstream functional assessment.
Fig.1 Flow cytometric analysis of N3 peptide binding to infective and non-infective Trypanosoma cruzi forms.1,4
In this study, investigators screened a phage peptide display library against the infective form of Trypanosoma cruzi and identified the N3 peptide as the most frequently recovered sequence after three rounds of selection. Follow-up flow cytometry analysis showed that the N3 peptide bound preferentially to the infective trypomastigote and amastigote forms, while showing weaker binding to non-infective epimastigotes and no significant binding to host Vero cells. Additional infection assays further showed that N3 reduced parasite invasion of Vero cells. This case connects selective phage display enrichment with binding specificity assessment and functional follow-up in a single workflow.
Fig.2 Flow cytometric analysis of antigen-specific phage binding in a cell-based phage display model.2,4
A second study is particularly relevant for projects involving cell-based phage display screening. The authors established an optimized flow cytometry-guided workflow using transgenic HEK293 cells and wildtype control cells to detect antigen-specific phage binding under a cell-based format. In the model system, a polyclonal phage library containing a well-characterized anti-FITC binder produced a clear antigen-specific binding signal on streptavidin-FITC-labeled transgenic HEK293 cells, while no comparable signal was observed on wildtype control cells. This case supports the value of cell-based phage display for target discovery projects in which native presentation, cell-surface accessibility, or context-dependent recognition may influence screening performance.
Fig.3 Binding validation and specificity assessment of anti-TIM3 and anti-TIGIT candidate antibodies.3,4
In this study, phage display-derived candidates against TIM3 and TIGIT were reformatted as IgG and advanced into binding validation and specificity assessment. The final candidates were evaluated using a homogeneous fluorescence-based binding assay and flow cytometry, and their binding profiles were compared with reference antibodies. The study further examined specificity in HEK293 cells overexpressing selected targets and confirmed endogenous TIM3 binding by the 6E9 candidate in immune-relevant cell models. This case shows how phage display hits can be carried forward into a more structured validation workflow to confirm target engagement and support candidate prioritization.
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
